Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression

被引：0
|
作者：
Katelin R. Haynes
Hsu-Wen Tseng
Michaela Kneissel
Tibor T. Glant
Matthew A. Brown
Gethin P. Thomas
机构：
[1] Translational Research Institute,The University of Queensland Diamantina Institute
[2] Princess Alexandra Hospital,Musculoskeletal Disease Area
[3] Novartis Institutes for Biomedical Research,Section of Molecular Medicine, Department of Orthopedic Surgery
[4] Rush University Medical Center,undefined
来源：
BMC Musculoskeletal Disorders | / 16卷
关键词：
Ankylosing spondylitis; Sclerostin; Wnt inhibitor; Mouse model; Bone formation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression
    Haynes, Katelin R.
    Tseng, Hsu-Wen
    Kneissel, Michaela
    Glant, Tibor T.
    Brown, Matthew A.
    Thomas, Gethin P.
    BMC MUSCULOSKELETAL DISORDERS, 2015, 16
  • [2] Serum sclerostin as a biomarker of disease activity in ankylosing spondylitis in correlation with radiographic imaging
    Sakrana, Nouran Medhat Abd El Samad
    Badr, Nevine Mohamed ElSayed
    Hassan, Manar Ahmed Azab
    Hassan, Marwa Ahmed Kamel
    EGYPTIAN RHEUMATOLOGY AND REHABILITATION, 2024, 51 (01)
  • [3] Altered Skeletal Expression of Sclerostin and Its Link to Radiographic Progression in Ankylosing Spondylitis
    Appel, Heiner
    Ruiz-Heiland, Gisela
    Listing, Joachim
    Zwerina, Jochen
    Herrmann, Martin
    Mueller, Ruediger
    Haibel, Hildrun
    Baraliakos, Xenofon
    Hempfing, Axel
    Rudwaleit, Martin
    Sieper, Joachim
    Schett, Georg
    ARTHRITIS AND RHEUMATISM, 2009, 60 (11): : 3257 - 3262
  • [4] Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta
    Roschger, Andreas
    Roschger, Paul
    Keplingter, Petra
    Klaushofer, Klaus
    Abdullah, Sami
    Kneissel, Michaela
    Rauch, Frank
    BONE, 2014, 66 : 182 - 188
  • [5] Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
    van der Heijde, Desiree
    Braun, Juergen
    Deodhar, Atul
    Baraliakos, Xenofon
    Landewe, Robert
    Richards, Hanno B.
    Porter, Brian
    Readie, Aimee
    RHEUMATOLOGY, 2019, 58 (03) : 388 - 400
  • [6] Early anti-inflammatory intervention ameliorates axial disease in the proteoglycan-induced spondylitis mouse model of ankylosing spondylitis
    Tseng, Hsu-Wen
    Glant, Tibor T.
    Brown, Matthew A.
    Kenna, Tony J.
    Thomas, Gethin P.
    Pettit, Allison R.
    BMC MUSCULOSKELETAL DISORDERS, 2017, 18
  • [7] Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis
    Sun, Wenjia
    Tian, Lizhen
    Jiang, Lichun
    Zhang, Songzhao
    Zhou, Meiju
    Zhu, Jianing
    Xue, Jing
    CLINICAL RHEUMATOLOGY, 2019, 38 (04) : 989 - 995
  • [8] Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis
    Wenjia Sun
    Lizhen Tian
    Lichun Jiang
    Songzhao Zhang
    Meiju Zhou
    Jianing Zhu
    Jing Xue
    Clinical Rheumatology, 2019, 38 : 989 - 995
  • [9] Radiographic Progression in Ankylosing Spondylitis: From Prognostication to Disease Modification
    Sari, Ismail
    Haroon, Nigil
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (12)
  • [10] Radiographic Progression in Ankylosing Spondylitis: From Prognostication to Disease Modification
    Ismail Sari
    Nigil Haroon
    Current Rheumatology Reports, 2018, 20
12345